Dover, United States
Recross Cardio Inc. is an innovative player in the Health Care and Medical Devices sectors, driven by its bold ambition to lead the next generation of medical solutions. Founded in 2021, the company has headquartered its operations in the United States. It is making strides towards addressing one of the most critical risks in stroke management today: patent foramen ovale (PFO).
With the aim of reducing recurrent ischemic strokes in patients with PFO-associated stroke, Recross Cardio Inc. has developed the P3 Occluder System. Notably, the company has initiated an FDA-approved Early Feasibility Study (EFS), known as The PROTEA-PFO Study, to validate the safety and efficacy of this breakthrough device. This aligns with their core mission of innovative risk reduction in stroke management.
Although Recross Cardio has not secured a recent investment, the groundbreaking potential and early investigative progress present a compelling opportunity for forward-thinking investors in the medical devices field.
